Investigational Drug Information for Eldecalcitol
✉ Email this page to a colleague
What is the drug development status for Eldecalcitol?
Eldecalcitol is an investigational drug.
There have been 6 clinical trials for Eldecalcitol.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2023.
The most common disease conditions in clinical trials are Osteoporosis, Osteoporosis, Postmenopausal, and Bone Diseases, Metabolic. The leading clinical trial sponsors are Shinshu University, Chugai Pharma China Co., Ltd., and e-GLORIA trial Protocol Review Committee.
There are four US patents protecting this investigational drug and one hundred and fifty-three international patents.
Summary for Eldecalcitol
| US Patents | 4 |
| International Patents | 153 |
| US Patent Applications | 62 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 50 |
| Clinical Trial Progress | Phase 1 (2023-05-01) |
| Vendors | 47 |
Recent Clinical Trials for Eldecalcitol
| Title | Sponsor | Phase |
|---|---|---|
| Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis | Chugai Pharma China Co., Ltd. | Phase 4 |
| Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Phase 4 |
| Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis. | Chugai Pharma China Co., Ltd. | Phase 4 |
Clinical Trial Summary for Eldecalcitol
Top disease conditions for Eldecalcitol
Top clinical trial sponsors for Eldecalcitol
US Patents for Eldecalcitol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Eldecalcitol | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Eldecalcitol | ⤷ Sign Up | Pharmaceutical propylene glycol solvate compositions | McNeil-PPC, Inc. (Skillman, NJ) | ⤷ Sign Up |
| Eldecalcitol | ⤷ Sign Up | Pharmaceutical co-crystal compositions | University of South Florida (Tampa, FL) The Regents of the University of Michigan (Ann Arbor, MI) Transform Pharmaceuticals, Inc. (Lexington, MA) | ⤷ Sign Up |
| Eldecalcitol | ⤷ Sign Up | Vitamin D receptor agonists to treat diseases involving CXCL12 activity | Salk Institute for Biological Studies (La Jolla, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Eldecalcitol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Eldecalcitol | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Eldecalcitol | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Eldecalcitol | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Eldecalcitol | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Eldecalcitol | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Eldecalcitol | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
